Photoimmunotherapy: Comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 620-632

  Sato, Kazuhide ^a   Watanabe, Rira ^a   Hanaoka, Hirofumi ^a   Harada, Toshiko ^a   Nakajima, Takahito ^a   Kim, Insook ^b   Paik, Chang H ^c   Choyke, Peter L ^a   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Epidermal growth factor receptor; Monoclonal antibody; NIR fluorescence; Pharmacokinetics; Photoimmunotherapy

Indexed keywords

CETUXIMAB IR 700; EPIDERMAL GROWTH FACTOR RECEPTOR; IR 700; PANITUMUMAB IR 700; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG; CETUXIMAB; MONOCLONAL ANTIBODY; PANITUMUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIARY EXCRETION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL DAMAGE; CELL DEATH; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RETENTION; DRUG TUMOR LEVEL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFRARED RADIATION; INTERNALIZATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHOTOIMMUNOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; DRUG SCREENING; HUMAN; IMMUNOTHERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; PHOTOSENSITIZING AGENTS; PHOTOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899485027     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.01.006     Document Type: Article

References (33)

1. Dubessy C., Merlin J.M., Marchal C., Guillemin F. Spheroids in radiobiology and photodynamic therapy. Crit. Rev. Oncol. Hematol. 2000, 36:179-192.
2. Eng C. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist 2010, 15:73-84.
3. Gialeli C., Kletsas D. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Curr. Med. Chem. 2009, 29:3797-3804.
4. Graff C.P., Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003, 63:1288-1296.
5. Koefoed K., Steinaa L., Søderberg J.N., Kjær I., Jacobsen H.J., Meijer P.-J., Haurum J.S., Jensen A., Kragh M., Andersen P.S., Pedersen M.W. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011, 3:584-595.
6. Laderoute K.R., Murphy B.J., Short S.M., Grant T.D., Knapp A.M., Sutherland R.M., Park M. Enhancement of transforming growth factor-a. Synthesis in multicellular tumour spheroids of A431 squamous carcinoma cells. Br. J. Cancer 1992, 2:157-162.
7. Lee S.Y., Jeon H.M., Kim C.H., Ju M.K., Bae H.S., Park H.G., Lim S.-C., Han S.I., Kang H.S. Homeobox gene Dlx-2 is implicated in metabolic stress-induced necrosis. Mol. Cancer 2011, 10:113.
8. Markovic A., Chung C.H. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev. Anticancer Ther. 2012, 12:1149-1159.
9. Mew D., Wat C., Towers G.H.N., Levy J.G. Photoimmunotherapy: treatment of animal tumors with tumor-specific. J.Immunol. 1983, 130:1473-1477.
10. Mitsunaga M., Nakajima T., Sano K., Choyke P.L., Kobayashi H. Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug. Chem. 2012, 23:604-609.
11. Mitsunaga M., Nakajima T., Sano K., Kramer-Marek G., Choyke P.L. Immediate invivo target-specific cancer cell death after near infrared photoimmunotherapy. BMC Cancer 2012, 12:1.
12. Mitsunaga M., Ogawa M., Kosaka N., Rosenblum L.T., Choyke P.L. Cancer cell - selective invivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 2011, 17:1685-1691.
13. Nakajima T., Sano K., Choyke P.L., Kobayashi H. Improving the efficacy of photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics 2013, 3:357-365.
14. Nakajima T., Sano K., Mitsunaga M., Choyke P.L., Kobayashi H. Real-time monitoring of invivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging. Cancer Res. 2012, 72:4622-4628.
15. Norguet E., Dahan L., Seitz J.-F. Targeting esophageal and gastric cancers with monoclonal antibodies. Curr. Top. Med. Chem. 2012, 12:1678-1682.
16. Ogawa M., Regino C.A.S., Seidel J., Green M.V., Xi W., Williams M., Kosaka N., Choyke P.L., Kobayashi H. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug. Chem. 2009, 20:2177-2184.
17. Raben N., Shea L., Hill V., Plotz P. Monitoring Autophagy in Lysosomal Storage Disorders. Methods in Enzymology 2009, Elsevier Inc. first ed.
18. Reichert J.M., Rosensweig C.J., Faden L.B., Dewitz M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 2005, 23:1073-1078.
19. Salfeld J.G. Isotype selection in antibody engineering. Nat. Biotechnol. 2007, 25:1369-1372.
20. Sano K., Mitsunaga M., Nakajima T., Choyke P.L., Kobayashi H. Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET. J.Nucl. Med. 2013, 54:770-775.
21. Sano K., Nakajima T., Ali T., Bartlett D.W., Wu A.M., Kim I., Paik C.H., Choyke P.L., Kobayashi H. Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging. J.Biomed. Opt. 2013, 18:101304.
22. Sano K., Nakajima T., Choyke P.L., Kobayashi H. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 2013, 7:717-724.
23. Sano K., Nakajima T., Miyazaki K., Ohuchi Y., Ikegami T., Choyke P.L., Kobayashi H. Short PEG-linkers improve the performance of targeted, activatable monoclonal antibody-indocyanine green optical imaging probes. Bioconjug. Chem. 2013, 24:811-816.
24. Sato K., Watanabe T., Wang S., Kakeno M., Matsuzawa K., Matsui T., Yokoi K., Murase K., Sugiyama I., Ozawa M., Kaibuchi K. Numb controls E-cadherin endocytosis through p120 catenin with aPKC. Mol. Biol. Cell 2011, 22:3103-3119.
25. Smith S.M., Flentke G.R., Garic A. Developmental toxicology. Methods Mol. Biol. 2012, 889:85-103.
26. Stinchcombe T.E., Socinski M.A. Targeted therapies: biomarkers in NSCLC for selecting cetuximab therapy. Nat. Rev. Clin. Oncol. 2010, 7:426-428.
27. Tebbutt N., Pedersen M.W., Johns T.G. Targeting the ERBB family in cancer: couples therapy. Nat. Rev. Cancer 2013, 13:663-673.
28. Tung Y.-C., Hsiao A.Y., Allen S.G., Torisawa Y., Ho M., Takayama S. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011, 136:473-478.
29. Vecchione L., Jacobs B., Normanno N., Ciardiello F., Tejpar S. EGFR-targeted therapy. Exp. Cell Res. 2011, 317:2765-2771.
30. Waldmann T.A. Immunotherapy: past, present and future. Nat. Med. 2003, 9:269-277.
31. Waleh N.S., Gallo J., Grant T.D., Murphy B.J., Kramer R.H., Sutherland R.M. Selective down-regulation of integrin receptors in spheroids of squamous cell carcinoma. Cancer Res. 1994, 54:838-843.
32. Yamaguchi H., Chang S.-S., Hsu J.L., Hung M.-C. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene 2013, 1-9.
33. Yarden Y., Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 2012, 12:553-563.